NASDAQ:NUVA - NuVasive Stock Price, Forecast & News

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings data on Thursday, February, 20th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.09. The medical device company had revenue of $310.40 million for the quarter, compared to the consensus estimate of $304.93 million. NuVasive had a net margin of 4.15% and a return on equity of 14.93%. NuVasive's quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $0.69 earnings per share. View NuVasive's Earnings History.

NuVasive is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for NuVasive.

NuVasive updated its FY20 earnings guidance on Thursday, February, 20th. The company provided EPS guidance of $2.55-2.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.60. The company issued revenue guidance of $1.21-1.24 billion, compared to the consensus revenue estimate of $1.23 billion.

16 brokerages have issued 12 month target prices for NuVasive's stock. Their forecasts range from $55.00 to $93.00. On average, they anticipate NuVasive's stock price to reach $79.67 in the next year. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for NuVasive.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NuVasive.

News articles about NUVA stock have been trending negative on Saturday, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NuVasive earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the near future. View News Stories for NuVasive.

NuVasive saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,200,000 shares, an increase of 7.7% from the January 15th total of 3,900,000 shares. Based on an average daily volume of 497,800 shares, the short-interest ratio is presently 8.4 days. Currently, 8.1% of the shares of the company are short sold. View NuVasive's Current Options Chain.

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include Incyte (INCY), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Starbucks (SBUX), Alibaba Group (BABA), Global Sources Ltd. (Bermuda) (GSOL), Intel (INTC), Celgene (CELG) and Gilead Sciences (GILD).

NuVasive's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Anchor Capital Advisors LLC (2.41%), Victory Capital Management Inc. (1.84%), Victory Capital Management Inc. (1.48%), Eagle Asset Management Inc. (1.42%), Geode Capital Management LLC (1.38%) and Charles Schwab Investment Management Inc. (0.77%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Institutional Ownership Trends for NuVasive.

NUVA stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Champlain Investment Partners LLC, Victory Capital Management Inc., Thrivent Financial for Lutherans, AQR Capital Management LLC, Eagle Asset Management Inc., Fort Washington Investment Advisors Inc. OH and Alliancebernstein L.P.. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Insider Buying and Selling for NuVasive.

NUVA stock was purchased by a variety of institutional investors in the last quarter, including Anchor Capital Advisors LLC, Panagora Asset Management Inc., Renaissance Technologies LLC, Victory Capital Management Inc., Copper Rock Capital Partners LLC, WCM Investment Management LLC, Bank of Montreal Can and UBS Group AG. View Insider Buying and Selling for NuVasive.

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NUVA stock can currently be purchased for approximately $75.16.

NuVasive has a market capitalization of $3.91 billion and generates $1.10 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.23 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.View Additional Information About NuVasive.

The official website for NuVasive is http://www.nuvasive.com/.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]